Consensus Process: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The endocrine society, the diabetes Technology society, and the european society of endocrinology reviewed and commented on preliminary drafts of these guidelines.
Conclusions:
The Task Force evaluated three potential uses of CGM: 1) real-time CGM in adult hospital settings; 2) real-time CGM in children and adolescent outpatients; and 3) real-time CGM in adult outpatients. The Task Force used the best available data to develop evidence-based recommendations about where CGM can be beneficial in maintaining target levels of glycemia and limiting the risk of hypoglycemia. Both strength of recommendations and quality of evidence were accounted for in the guidelines.
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Abbreviations: CGM, Continuous glucose monitoring; CIT, conventional insulin therapy; HbA1c, glycosylated hemoglobin; ICU, intensive care unit; IIT, intensive insulin therapy; ISF, interstitial fluid; MDI, multiple daily injections; MICU, medical ICU; POC, point-of-care; RT-CGM, real-time CGM; SMBG, self-monitoring of blood glucose; T1DM, type 1 diabetes mellitus.
A n e n d o C r i n e s o C i e t y C l i n i C A l P r A C t i C e G u i d e l i n e 4 SuMMAry Of rECOMMEndATiOnS 1 .0. real-time continuous glucose monitoring (rT-CGM) in adult hospital settings 1.1. We recommend against the use of RT-CGM alone for glucose management in the intensive care unit (iCu) or operating room until further studies provide sufficient evidence for its accuracy and safety in those settings (1| ).
2.0. rT-CGM in children and adolescent outpatients 2.1. We recommend that RT-CGM with currently approved devices be used by children and adolescents with type 1 diabetes mellitus (T1dM) who have achieved glycosylated hemoglobin (Hba1c) levels below 7.0% because it will assist in maintaining target Hba1c levels while limiting the risk of hypoglycemia (1| ).
2.2.
We recommend RT-CGM devices be used with children and adolescents with T1dM who have Hba1c levels ≥ 7.0% who are able to use these devices on a nearly daily basis (1| ).
2.3.
We make no recommendations for or against the use of RT-CGM by children with T1dM who are less than 8 yr of age.
2.4.
We suggest that treatment guidelines be provided to patients to allow them to safely and effectively take advantage of the information provided to them by RT-CGM (2| ).
2.5.
We suggest the intermittent use of CGM systems designed for short-term retrospective analysis in pediatric patients with diabetes in whom clinicians worry about nocturnal hypoglycemia, dawn phenomenon, and postprandial hyperglycemia; in patients with hypoglycemic unawareness; and in patients experimenting with important changes to their diabetes regimen [such as instituting new insulin or switching from multiple daily injections (Mdi) to pump therapy] (2| ).
rT-CGM in adult outpatients
3.1. We recommend that RT-CGM devices be used by adult patients with T1dM who have Hba1c levels of at least 7.0% and who have demonstrated that they can use these devices on a nearly daily basis (1| ).
3.2.
We recommend that RT-CGM devices be used by adult patients with T1dM who have Hba1c levels less than 7.0% and who have demonstrated that they can use these devices on a nearly daily basis (1| ).
3.3.
We suggest that intermittent use of CGM systems designed for short-term retrospective analysis may be of benefit in adult patients with diabetes to detect nocturnal hypoglycemia, the dawn phenomenon, and postprandial hyperglycemia, and to assist in the management of hypoglycemic unawareness and when significant changes are made to their diabetes regimen (such as instituting new insulins or switching from Mdi to pump therapy) (2| ).
METhOd Of dEvElOPMEnT Of EvidEnCE-BASEd CliniCAl PrACTiCE GuidElinES
The Clinical Guidelines subcommittee of The endocrine society deemed continuous glucose monitoring (CGM) a priority area in need of practice guidelines and appointed a Task Force to formulate evidencebased recommendations. The Task Force followed the approach recommended by the Grading of Recommendations, assessment, development, and evaluation (GRade) workgroup, an international group with expertise in development and implementation of evidence-based guidelines (1) . a detailed description of the grading scheme has been published elsewhere (2) . The Task Force used the best available research evidence that Task Force members identified and one commissioned systematic literature review of randomized controlled trials of CGM use (3) to inform some of the recommendations. The Task Force also used consistent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. in terms of the strength of the recommendation, strong recommendations use the phrase "we recommend" and the number 1, and weak recommendations use the phrase "we suggest" and the number 2.
Cross-filled circles indicate the quality of the evidence, such that denotes very low quality evidence; , low quality;
, moderate quality; and , high quality. The Task Force has confidence that persons who receive care according to the strong recommendations will derive, on average, more good than harm. Weak recommendations require more careful consideration of the person's circumstances, values, and preferences to determine the best course of action. linked to each recommendation is a description of the evidence and the values that panelists considered in making the recommendation. all of our recommendations are expert opinions and are evidence based. some of these opinions are based on stronger evidence than others. For strong recommendations with GRade 1 evidence, the Task Force has made recommendations, and for weak recommendations with GRade 2 evidence, the Task Force has made suggestions. For recommendations in this guideline that are based on low-quality to very low-quality evidence, the reader should note that our implicit recommendation is for more research.
The task force recognizes that CGM may place educational and practical burdens on patients and their families and on diabetes care providers who must be available to support, advise, and educate them. We also recognize that there are costs associated with the use of this technology according to our recommendations and that ultimately, the routine use of this technology will depend on an evolving calculus of cost vs. effectiveness. We have considered the cost-benefit issues related to the use of CGM and feel that the clinical benefits justify the costs in a wide range of patients, but that these values may not be universally shared in some healthcare settings (e.g. those with resource-constrained settings, clinics unable to provide adequate support to patients and families). individuals or health systems may disagree with our relative valuation, and in these cases our recommendations may not apply. it may then be necessary to modify these recommendations accordingly.
inTrOduCTiOn
People who have diabetes mellitus face daily challenges in managing glycemic levels, as well as avoiding hypoglycemic and hyperglycemic excursions. Both severe hypoglycemia and extreme hyperglycemia have an immediate impact on mental and physical functioning. Moreover, the maintenance of glycemic control within near-normal limits has been shown to significantly decrease the development of secondary micro-and macrovascular complications to diabetes (4-6).
Capillary blood glucose measurements using portable devices have been used to assess blood glucose several times a day in an effort to provide the patient with reliable guidance for treatment (including dietary) measures to correct hypo-or hyperglycemia. However, even with frequent blood sampling for spot glucose measurements, some patients do not adequately manage their glycemic levels. it has been postulated that such patients may benefit from a system providing them with continuous real-time glucose readings. although this argument is intuitively easy to accept, there remain a number of caveats to take into account before accepting continuous monitoring of blood glucose as a routine (or even specialized) measure to improve glycemic control in diabetes.
First, maintaining direct access to the blood on a continuous basis for an extended period has proved impractical. Hence, a number of different techniques have been evaluated, including invasive and noninvasive methods for indirectly estimating blood glucose. second, the reliability in terms of accuracy and the precision of the various systems need proper documentation before being applied in routine care. Third, financial constraints require an ongoing evaluation of the socioeconomic consequences of these operating room until further studies provide sufficient evidence for its accuracy and safety in those settings (1| ).
Evidence
The study of van den Berghe et al. (8) (9) (10) (11) (12) (13) . a meta-analysis before the niCe-suGaR report, in fact, confirmed that there was no benefit to iiT (14) in the iCu population. Furthermore, these prospective, randomized controlled trials of iiT demonstrated that hypoglycemia was significantly more common in those receiving iiT than in those treated with CiT. The niCe-suGaR study showed, in fact, an increased mortality rate in those treated with iiT (12) ( Table 1) . although the reasons for this increased rate are unclear, the finding is consistent with a retrospective analysis showing that hypoglycemia was an independent risk factor for mortality (15 CGM may have an advantage over POC testing in that it has the potential to reduce the possibility of unknown hypoglycemic events that may occur between POC measurements. These devices use isF rather than blood to measure glucose, but the relationship of isF to blood in critically ill patients has been investigated only to a limited degree. several studies of CGM have evaluated the effects of conditions that are common in the iCu, such as hypotension with or without inotrope use, hypothermia, edema, renal and hepatic failure, hyperinsulinemia, and acidosis, but these studies were small and generally not powered to assess each of those variables (Table 2 ) (31-37). For example, de Block et al. (31), in a study of 50 adult iCu patients, noted worse accuracy in patients on inotropes and better accuracy in those in acute renal failure and septic shock compared with patients on no inotropes and without these conditions. However, Holzinger et al. (33) found that there was no significant effect on accuracy in 27 iCu patients treated with norepinephrine for shock compared with 23 without shock, and a lack of iatrogenic hypoglycemia after insulin therapy was not associated with a higher mortality risk (16).
These trials used a variety of bedside point-of-care (POC) devices for testing glucose, which are listed (when specified) in Table 1 . The listed devices use glucose dehydrogenase for glucose determination. Recently, the Food and drug administration (Fda) has warned that this method is subject to false elevation by maltose, icodextrine, galactose, and xylose, although the Fda has not proscribed their use in the hospital (17) . it is unlikely, although not impossible, that patients in intensive management studies were subject to such errors. On the other hand, devices that use glucose oxidase are potentially subject to falsely lower than actual values in settings where there is high oxygen tension produced by supplemental oxygen (18) . Both methods may be affected by a variety of medications. importantly, the requirements for accuracy in a critical care setting have not yet been determined. Kost et al. (19) have suggested that the margins of error for blood glucose measurement should be within 15 mg/dl of the reference measurement for blood sugars less than 100 mg/dl and within 15% if above 100 mg/dl in critical care settings. it should be noted that the international Organization for standardization (isO) (20) suggested that the margin of error should be within 15 mg/dl for blood sugars less than 75 mg/dl. in addition to the issue of what standards should be applied, POC testing itself (rather than laboratory testing) in critically ill patients is controversial because of unresolved questions about the effects on accuracy of common conditions, e.g. acidosis, hypothermia, and hypotension; or medications, e.g. dopamine, mannitol, acetaminophen, and pressor use. These circumstances reduce tissue perfusion, which may uncouple the usual relationship between the sc and circulatory glucose. Thus, results may differ depending not only on the source of the sample-capillary, vein, or artery-but also on the concomitant cause and treatment of the patient's iCu stay. Of several studies investigating the accuracy of POC testing in the iCu, some found adequate accuracy if arterial samples were used (18, 21) , whereas others generally showed marginal or clinically unacceptable accuracy with capillary samples (22-28). despite these findings, the life-threatening zone. in iCu patients with continuous insulin infusions, Rabiee et al. (41) compared the dexCom to three different methods of glucose determination-two with capillary blood from finger sticks (accu-Chek and OneTouch) and one from serum (Hitachi 917), which was used as the "gold standard" for clinical decisions. There were 85 paired values with the Hitachi 917, and 100% of values in the a and B zones. However, when these results and the paired data with the accu-Chek (1065 paired values compared with dexcom) and OneTouch (232 paired values compared with dexcom) were more closely examined, the CGM generally overestimated the actual serum glucose and missed 50% of the 30 actual hypoglycemic episodes as determined by accu-Chek, leading the authors to conclude that it was not sufficiently safe to be used in an iCu setting. Blood glucose measurements on POC devices have been used as reference methods for CGM accuracy studies, but these devices provide readings with up to a 20% bias (or greater in some circumstances) compared to reference values. in hospitalized patients, anemia, abnormal oxygen tension, and hypotension can all degrade accuracy of these devices and make it difficult to assess the simultaneous performance of CGM. This study is a harbinger of an "artificial pancreas" and represents a valuable and rapidly progressing area of research to determine whether or not the application of sophisticated model predictive controller algorithms will be sufficient to overcome the inherent inaccuracies of CGM technology.
Values and preferences
The Task Force recommends against using CGM in iCu settings where patients are likely to be unable to provide feedback about hypoglycemic symptoms. and 180 mg/dl, and combined outcomes involving Hba1c coupled with hypoglycemia) favored the CGM group compared with the control group. Treatment effects were generally similar across age groups.
Recommendation
2.2.
We recommend RT-CGM devices be used with children and adolescents with T1dM who have Hba1c levels 7.0% who are able to use these devices on a nearly daily basis (1| ).
Evidence
The (61) . subjects in that study aged 8-17 yr who wore the CGM device 6-7 d/wk lowered Hba1c levels by 0.8% without increasing the frequency of low sensor glucose concentrations (62) . Moreover, the improvement in glycemic control was maintained for a full 12 months in those subjects (21% of the pediatric cohort) who were able to continue the frequent use of these devices. it is also noteworthy that the incidence of severe hypoglycemia in the entire pediatric cohort was only 11.2 events per 100 patient-years over the 12 months of study. For comparison, the rate of severe hypoglycemia in intensively treated adolescents in the diabetes Control and Complications Trial was 86 events per 100 patient years (63) . Thus, CGM use may improve the safety of intensive treatment of children and adolescents with T1dM even when worn less than 6-7 d/wk.
Post hoc analyses of the JdRF CGM RCT data indicate that there are few strong predictors that can be used to identify which young patients with T1dM will use the sensor on a nearly daily basis. The only baseline characteristic other than older age that predicted near-daily CGM use was frequent daily blood glucose meter testing before entering the trial (64) .
additional data from the JdRF CGM RCT indicate that patients' perception of the inconvenience of using current CGM devices is the major obstacle to more consistent use of these systems (65) .
in a randomized, controlled, multicenter european/ israeli study of both children (ages 10-17 yr) and adults with T1dM whose Hba1c levels were less than 7.5%, a post hoc per protocol analysis demonstrated that time spent in hypoglycemia below 63 mg/dl was reduced by 64% (P < 0.001) in the children (66).
Recommendation
2.3.
We make no recommendations for or against the use of RT-CGM by children with T1dM who are less than 8 yr of age. More research in this field is needed.
Evidence
Randomized trials in younger age groups have been initiated, but no results have been reported yet. limited data from nonrandomized studies indicate that these devices can be used successfully in patients less than 8 yr of age (47, 67). The quality of evidence is insufficient to support recommendations for or against its use in this patient population at this time.
Recommendation
2.4.
Evidence
The direcnet study group (68) has developed and implemented useful guidelines for initiating the use of RT-CGM. Proper training is necessary for patients and healthcare professionals to use CGM properly (69) . additional studies are needed to evaluate the effectiveness of current and future guidelines, with regard to the timing of a premeal insulin bolus, using glucose trends during exercise, and using RT-CGM when initiating pramlintide therapy.
Recommendation
2.5.
We suggest the intermittent use of CGM systems designed for short-term retrospective analysis in pediatric patients with diabetes for whom clinicians worry about nocturnal hypoglycemia, dawn phenomenon, and postprandial hyperglycemia; in patients with hypoglycemic unawareness and in patients experimenting with important changes to their diabetes regimen (such as instituting new insulin or switching from Mdi to pump therapy) (2| ). These devices represent an alternative for patients who
rT-CGM in AdulT OuTPATiEnTS
Recommendation 3.1. We recommend that RT-CGM devices be used by adult patients with T1dM who have Hba1c levels of at least 7.0% and who have demonstrated they can use these devices on a nearly daily basis (1| ).
Evidence
The JdRF CGM RCT (59), the GuardControl study (60) , and O'Connell et al. (75) demonstrated that adults with Hba1c of at least 7.0% had a greater reduction in Hba1c with the use of RT-CGM than with intermittent sMBG. Furthermore, unlike findings with sMBG, the improvement in Hba1c with CGM is not accompanied by an increase in biochemical hypoglycemia (54, 60). The improvement in Hba1c in the CGM subjects in the 6-month JdRF trial was sustained during the 6-month observational period that followed completion of the trial (76) . This ongoing benefit occurred despite reduction in office visit frequency during this observational period to levels (2.7 ± 1.2 visits over 6 months) similar to routine care. Furthermore, the incidence rate of severe hypoglycemia declined from 20.5 events per 100 patient-years during the initial 6-month randomized trial to 12.1 events per 100 patient-years during the 6-month observational follow up. in a randomized, controlled, multicenter european/israeli study of both children (ages 10-17 yr) and adults with T1dM whose Hba1c levels were less than 7.5%, a post hoc per protocol analysis demonstrated that time spent in hypoglycemia below 63 mg/dl was reduced by 50% (P = 0.02) in the adults (66).
Recommendation
3.2.
cannot safely and effectively take advantage of the information provided to them by RT-CGM.
Evidence
When the MiniMed CGMs was first introduced for 3-d retrospective analysis of plasma glucose profiles, investigators quickly showed that this method of glucose monitoring revealed patterns of post-meal hyperglycemia and nocturnal hypoglycemia that were not evident during standard sMBG testing in children with T1dM (45, 47). several small clinical trials suggested that even one or two uses of the CGMs device could lead to treatment adjustments that had long-lasting improvements in metabolic control of T1dM (70) (71) (72) (73) . The validity of these findings has been cast in doubt by the results of RT-CGM studies that indicate the need for nearly daily use of the devices to obtain and maintain lowering in Hba1c levels (61) . nevertheless, in the judgment of many diabetes care providers, retrospective analysis of shortterm CGM profiles can be of benefit in individual patients in whom the causes of persistent elevations in Hba1c are unclear.
Sensor-augmented pump therapy vs. insulin pump and SMBG at onset in youth with T1D
use of CGM in combination with insulin pump therapy during the first year of diabetes does not appear to improve metabolic control in comparison to insulin pump therapy with standard sMBG when initiated in youth with T1d at the onset of the disease.
in the OnseT study that involved 160 youth (aged 1-16 yr) (74) , no significant difference in Hba1c levels was observed after 12 months in subjects randomized to sensor-augmented pump therapy (i.e. pump and CGM) in comparison with the use of insulin pumps and standard blood glucose meter monitoring.
detect nocturnal hypoglycemia, the dawn phenomenon, and postprandial hyperglycemia, and to assist in the management of hypoglycemic unawareness and when significant changes are made to their diabetes regimen (such as instituting new insulin or switching from Mdi to pump therapy) (2| ). These devices represent an alternative for patients who cannot safely and effectively take advantage of the information provided to them by RT-CGM.
Evidence
The studies and conclusions discussed in recommendation 2.6 pertain to adult patients as well as pediatric patients. There is also evidence that intermittent profiles can provide additional insights in adults with type 2 diabetes mellitus regarding glucose levels and the time in target range (77) .
COnCluSiOnS
CGM can be beneficial in maintaining target levels of glycemia and limiting the risk of hypoglycemia. The Task Force used best available data to make recommendations about the use of CGM in three clinical settings: 1) RT-CGM in adult hospital settings; 2) RT-CGM in children and adolescent outpatients; and 3) RT-CGM in adult outpatients. With varying degrees of strength of evidence and quality of evidence, the Task Force recommended the use of CGM in the second and third settings. The routine use of this technology will also depend in part on future determinations of its cost relative to its benefits. The Task Force recommended against using CGM in adult hospital settings at this time and can make no recommendations about the use of CGM in children less than 8 yr of age because of the paucity of data.
Evidence
The JdRF CGM study Group has demonstrated that in patients with T1dM who have achieved Hba1c levels less than 7.0%, RT-CGM use can reduce the frequency of biochemical hypoglycemia (which they defined as a blood glucose level of below 70 mg/dl) and help maintain Hba1c levels less than 7.0% compared with standard blood glucose monitoring over a 6-month study period. Of the 129 enrolled subjects, 62 (or 48%) were younger than 25, and 67 (or 52%) were more than 25 yr of age. The median time per day with a glucose level of 70 mg/dl or less as measured with CGM was less in the CGM group than in the control group; however, the difference was not statistically significant. in this study, almost all the other analyses (including the time per day ≤ 60 mg/dl, time per day between 71 and 180 mg/dl, and combined outcomes involving Hba1c coupled with hypoglycemia) favored the CGM group compared with the control group. Treatment effects were generally similar across age groups (59) . For the CGM users who were 25 yr and older, the incidence rate of severe hypoglycemia was 21.8 events per 100 person-years during the 6-month randomized controlled trial and 7.1 events per 100 person-years during the 6 months of continued CGM use after the conclusion of the randomized clinical trial (the observational period that followed the trial). For these CGM users whose Hba1c levels were below 7.0%, these incidences were 23.6 events per 100 person-years during the 6-month randomized controlled trial and 0 per 100 patient-years during the 6 months of continued CGM use after the conclusion of the randomized clinical trial (76) . This evidence of an ongoing learning curve and improvement in glycemic control over the long term points to the user dependence of CGM technology, and this may partly account for the failure of other randomized trials enrolling individuals with poorer glycemic control (55) to demonstrate a reduction in severe hypoglycemia. Developed independently by a team of experts, evidencebased, and vetted through a rigorous, multi-step peer review process, the Continuous Glucose Monitoring Guideline addresses:
• Real-time CGM in Adult Hospital Settings
• Real-time CGM in Children and Adolescent Outpatients
• Real-time CGM in Adult Outpatients
Other Endocrine Society Guidelines COMING SOON 
